An artificial intelligence-based tool may help physicians determine which newly diagnosed multiple myeloma patients are most likely to benefit from specific therapies, including immunotherapy and stem cell transplantation.
4 hours ago
0
0
Dana-Farber Cancer Institute investigators have developed an online, easy-to-use tool that more accurately predicts when a precursor blood condition called smoldering multiple myeloma is likely to turn into active cancer ...
Mar 24, 2026
0
4
At the American Society of Hematology Conference in Orlando, new results from the MajesTEC-3 study show that combining teclistamab with daratumumab could help people with myeloma whose cancer has come back or hasn't responded ...
Dec 9, 2025
0
17
Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific monoclonal antibody, and daratumumab, a CD38-directed monoclonal antibody, were 83% more likely to be alive ...
Dec 9, 2025
0
17
For more than a year, Diane Hunter, now 72, had been experiencing vague symptoms—pain in her spine and hips, nausea, exhaustion, thirst, and frequent urination. Her primary care physician had ruled out diabetes before finally ...
Nov 11, 2025
0
17
A new four-drug combination is highly effective and safe in patients with newly diagnosed multiple myeloma, according to data presented at the annual meeting of the American Society of Clinical Oncology (ASCO), held May 30 ...
May 30, 2025
0
31
How cancer patients relying on daratumumab feel physically before starting the therapy can predict how long they will live and how well they will respond to the anti-multiple myeloma (MM) drug, according to a new study published ...
May 14, 2025
0
16
Multiple myeloma is a type of blood cancer caused by a buildup of abnormal plasma cells in the bone marrow. As the abnormal plasma cells accumulate, they crowd out healthy cells and cause symptoms such as bone pain and tiredness.
Apr 25, 2025
0
20
A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer. High-risk SMM carries a higher likelihood ...
Dec 10, 2024
0
24
The treatment landscape for multiple myeloma, the second most common blood cancer, is shifting rapidly, with newly diagnosed patients increasingly being treated with a four-part drug combination that includes a new immunotherapy ...
May 24, 2024
0
64
